Johnson & Johnson: Defensive Stalwart Balances Growth and Dividend Resilience

# Johnson & Johnson Stock Analysis: Strong Earnings & Growth Potential | Investment Insights Podcast Explore Johnson & Johnson's impressive market performance in our latest episode as we analyze the healthcare giant trading near its 52-week high at $168. We break down their exceptional Q2 earnings report that exceeded expectations with $23.7B in revenue (up 6% year-over-year) and $2.77 EPS, prompting management to raise their full-year outlook by $2B. Discover why analysts remain bullish with price targets averaging $174 despite cautious trading volumes. We examine J&J's remarkable 63-year dividend increase streak (currently yielding over 3%) and how their Innovative Medicine and MedTech divisions are positioned to drive future growth. With a $400B+ market cap and strong financials, learn why Johnson & Johnson continues to be a preferred defensive investment in today's market. Perfect for investors seeking insights on blue-chip healthcare stocks with consistent performance and growth potential. #JohnsonAndJohnson #StockAnalysis #InvestmentStrategy #HealthcareStocks #DividendInvesting #WallStreetInsights For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.